Header Logo

Connection

Annette Langer-Gould to Multiple Sclerosis, Relapsing-Remitting

This is a "connection" page, showing publications Annette Langer-Gould has written about Multiple Sclerosis, Relapsing-Remitting.
  1. Improving quality, affordability, and equity of multiple sclerosis care. Ann Clin Transl Neurol. 2021 04; 8(4):980-991.
    View in: PubMed
    Score: 0.771
  2. Sex hormones and multiple sclerosis: another informative failure. Lancet Neurol. 2016 Jan; 15(1):22-3.
    View in: PubMed
    Score: 0.534
  3. Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J. 2014; 18(1):9-13.
    View in: PubMed
    Score: 0.468
  4. One can prevent post-partum MS relapses by exclusive breast feeding: yes. Mult Scler. 2013 Oct; 19(12):1567-8.
    View in: PubMed
    Score: 0.460
  5. Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosis. Arch Neurol. 2010 Jan; 67(1):51-7.
    View in: PubMed
    Score: 0.355
  6. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009 Jun; 29(2):104-6.
    View in: PubMed
    Score: 0.341
  7. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec; 63(12):1686-91.
    View in: PubMed
    Score: 0.287
  8. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr Neurol Neurosci Rep. 2006 May; 6(3):253-8.
    View in: PubMed
    Score: 0.275
  9. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28; 353(4):375-81.
    View in: PubMed
    Score: 0.259
  10. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 02 01; 77(2):184-191.
    View in: PubMed
    Score: 0.178
  11. Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn). 2019 Jun; 25(3):773-792.
    View in: PubMed
    Score: 0.170
  12. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler. 2012 Mar; 18(3):377-8.
    View in: PubMed
    Score: 0.099
  13. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88.
    View in: PubMed
    Score: 0.078
  14. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2003 Nov-Dec; 24(10):1941-5.
    View in: PubMed
    Score: 0.058

© 2024 Kaiser Permanente